{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:57:20Z","timestamp":1793505440697,"version":"4.5.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T00:00:00Z","timestamp":1681344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin\u2019s lymphoma worldwide and particularly in Africa, where the incidence of HIV is the highest in the world. R-CHOP is the standard of care regimen for DLBCL, but access to rituximab is limited in developing countries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a retrospective cohort study that included all HIV-negative patients with DLBCL who received R-CHOP at a single institution from January 2012 to December 2017. Clinical and demographic data were collected to assess factors that influenced survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seventy-three patients were included. Median age was 55 (17-76), 67.1% of patients were younger than 60 years, and 60.3% were female. Most presented with stages III\/IV disease (53.5%) but with good performance status (56.% PS 0 and 1). Progression-free survival at 3 and 5 years was 75% and 69%, and overall survival at 3 and 5 years was 77% and 74%, respectively. Median survival had not been reached with a median follow-up of 3.5 years(0.13-7.9). Overall survival was significantly affected by performance status (P\u2005=\u2005.04), but not by IPI or age. Survival was significantly associated with response to chemotherapy after 4-5 cycles of R-CHOP (P\u2005=\u20050.005).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Treatment of DLBCL with R-CHOP is feasible and can achieve good outcomes in resource-limited settings with rituximab-based chemotherapy. Poor performance status was the most important adverse prognostic factor in this cohort of HIV-negative patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyad069","type":"journal-article","created":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T09:24:47Z","timestamp":1677576287000},"page":"e756-e764","source":"Crossref","is-referenced-by-count":10,"title":["Diffuse Large B-Cell Lymphoma Treated With R-CHOP in a Resource-Limited Setting in South Africa: A Real-World Study"],"prefix":"10.1093","volume":"28","author":[{"given":"Zola","family":"Musimar","sequence":"first","affiliation":[{"name":"Radiation Oncology Department, Groote Schuur Hospital, University of Cape Town, Cape Town, Western Cape, Republic of South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mtonga","family":"Mpetani","sequence":"additional","affiliation":[{"name":"Radiation Oncology Department, Groote Schuur Hospital, University of Cape Town, Cape Town, Western Cape, Republic of South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy S","family":"Abramson","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center and the POETIC Fellowship Exchange Program, Dana Faber, Harvard Cancer Center, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce A","family":"Chabner","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center and the POETIC Fellowship Exchange Program, Dana Faber, Harvard Cancer Center, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zainab","family":"Mohamed","sequence":"additional","affiliation":[{"name":"Radiation Oncology Department, Groote Schuur Hospital, University of Cape Town, Cape Town, Western Cape, Republic of South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,4,13]]},"reference":[{"issue":"3","key":"2023090805143785300_CIT0001","first-page":"148","article-title":"Impact of rituximab (Rituxan) on the treatment of B-cell non-Hodgkin\u2019s lymphoma","volume":"35","author":"Dotan","year":"2010","journal-title":"P T"},{"issue":"4","key":"2023090805143785300_CIT0002","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/bjh.17811","article-title":"Molecular profiling in diffuse large B-cell lymphoma: why so many types of subtypes","volume":"196","author":"Morin","year":"2022","journal-title":"Br J Haematol."},{"issue":"3","key":"2023090805143785300_CIT0003","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/PPO.0000000000000450","article-title":"Molecular classification and treatment of diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma","volume":"26","author":"Roschewski","year":"2020","journal-title":"Cancer J."},{"issue":"5","key":"2023090805143785300_CIT0004","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/bjh.13885","article-title":"Non-Hodgkin lymphoma in Southern Africa: review of 487 cases from The International Non-Hodgkin Lymphoma Classification Project","volume":"172","author":"Perry","year":"2016","journal-title":"Br J Haematol."},{"key":"2023090805143785300_CIT0005","first-page":"1","article-title":"Impact of HIV infection on the clinical presentation and survival of non-Hodgkin lymphoma: a prospective observational study from Botswana","volume":"4","author":"Milligan","year":"2018","journal-title":"J Glob Oncol"},{"issue":"7","key":"2023090805143785300_CIT0006","doi-asserted-by":"crossref","first-page":"844","DOI":"10.4067\/S0034-98872013000700003","article-title":"Comparison between CHOP-like and R-CHOP in diffuse large B cell and follicular lymphoma","volume":"141","author":"Oliver","year":"2013","journal-title":"Rev Med Chil."},{"issue":"22","key":"2023090805143785300_CIT0007","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1200\/JCO.2005.09.137","article-title":"Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia","volume":"23","author":"Sehn","year":"2005","journal-title":"J Clin Oncol."},{"issue":"4","key":"2023090805143785300_CIT0008","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med."},{"issue":"3","key":"2023090805143785300_CIT0009","first-page":"3602","article-title":"Diffuse large B-cell lymphoma: 10 years\u2019 real-world clinical experience with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone","volume":"15","author":"Horvat","year":"2018","journal-title":"Oncol Lett"},{"issue":"11","key":"2023090805143785300_CIT0010","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1470-2045(11)70235-2","article-title":"CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group","volume":"12","author":"Pfreundschuh","year":"2011","journal-title":"Lancet Oncol."},{"issue":"7","key":"2023090805143785300_CIT0011","doi-asserted-by":"crossref","first-page":"e1008","DOI":"10.1016\/S2214-109X(21)00181-9","article-title":"Safety and efficacy of rituximab in patients with diffuse large B-cell lymphoma in Malawi: a prospective, single-arm, non-randomised phase 1\/2 clinical trial","volume":"9","author":"Kimani","year":"2021","journal-title":"Lancet Glob Health"},{"issue":"3","key":"2023090805143785300_CIT0012","doi-asserted-by":"crossref","first-page":"e0150445","DOI":"10.1371\/journal.pone.0150445","article-title":"CHOP chemotherapy for aggressive non-Hodgkin lymphoma with and without HIV in the antiretroviral therapy era in Malawi","volume":"11","author":"Gopal","year":"2016","journal-title":"PLoS One."},{"issue":"2","key":"2023090805143785300_CIT0013","doi-asserted-by":"crossref","first-page":"123","DOI":"10.17925\/EOH.2012.08.02.123","article-title":"Management strategies for elderly patients with diffuse large B-cell lymphoma","volume":"8","author":"Nastoupil","year":"2012","journal-title":"Eur Oncol Haematol"},{"key":"2023090805143785300_CIT0014","doi-asserted-by":"crossref","first-page":"628744","DOI":"10.3389\/fpubh.2021.628744","article-title":"Availability, affordability, access, and pricing of anti-cancer medicines in low- and middle-income countries: a systematic review of literature","volume":"9","author":"Ocran Mattila","year":"2021","journal-title":"Front Public Health."},{"issue":"6","key":"2023090805143785300_CIT0015","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/j.1365-2141.2011.08772.x","article-title":"Lymphomas in sub-Saharan Africa\u2014what can we learn and how can we help in improving diagnosis, managing patients and fostering translational research","volume":"154","author":"Naresh","year":"2011","journal-title":"Br J Haematol."},{"issue":"6","key":"2023090805143785300_CIT0016","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1524-4733.2010.00737.x","article-title":"Cost-effectiveness of the addition of rituximab to CHOP chemotherapy in first-line treatment for diffuse large B-cell lymphoma in a population-based observational cohort in British Columbia, Canada","volume":"13","author":"Johnston","year":"2010","journal-title":"Value Health."},{"issue":"9","key":"2023090805143785300_CIT0017","doi-asserted-by":"crossref","first-page":"e1305","DOI":"10.1016\/S2214-109X(21)00261-8","article-title":"Comparison of best supportive care, CHOP, or R-CHOP for treatment of diffuse large B-cell lymphoma in Malawi: a cost-effectiveness analysis","volume":"9","author":"Painschab","year":"2021","journal-title":"Lancet Glob Health"},{"issue":"6","key":"2023090805143785300_CIT0018","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.arcmed.2015.07.004","article-title":"Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma","volume":"46","author":"Jaime-P\u00e9rez","year":"2015","journal-title":"Arch Med Res."},{"key":"2023090805143785300_CIT0019","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2147\/IJGM.S223882","article-title":"Identifying key challenges facing healthcare systems in Africa and potential solutions","volume":"12","author":"Oleribe","year":"2019","journal-title":"Int J Gen Med"},{"issue":"4","key":"2023090805143785300_CIT0020","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1182\/blood.V86.4.1460.bloodjournal8641460","article-title":"International prognostic index for aggressive non-Hodgkin\u2019s lymphoma is valid for all malignancy grades","volume":"86","author":"Hermans","year":"1995","journal-title":"Blood."},{"issue":"3","key":"2023090805143785300_CIT0021","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.clml.2011.11.004","article-title":"Ten-year relative survival and causes of death in elderly patients treated with R-CHOP or CHOP in the GELA LNH-985 trial","volume":"12","author":"Mounier","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"23","key":"2023090805143785300_CIT0022","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood.2019002729","article-title":"International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI","volume":"135","author":"Ruppert","year":"2020","journal-title":"Blood."},{"issue":"4","key":"2023090805143785300_CIT0023","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1179\/1607845412Y.0000000006","article-title":"Is there a benefit to adding rituximab to CHOP in the overall survival of patients with B-cell non-Hodgkin\u2019s lymphoma in a developing country","volume":"17","author":"Ruiz-Delgado","year":"2012","journal-title":"Hematology"},{"key":"2023090805143785300_CIT0024","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1186\/1471-2407-14-586","article-title":"Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis","volume":"14","author":"Khor","year":"2014","journal-title":"BMC Cancer"},{"issue":"8","key":"2023090805143785300_CIT0025","first-page":"e9620","article-title":"Validation of the International prognostic index and subsequent revisions for diffuse large B-cell lymphoma in patients from the Middle East and North Africa Region","volume":"12","author":"Alamer","year":"2020","journal-title":"Cureus"},{"issue":"5","key":"2023090805143785300_CIT0026","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol."},{"issue":"27","key":"2023090805143785300_CIT0027","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol."},{"key":"2023090805143785300_CIT0028","doi-asserted-by":"crossref","first-page":"796962","DOI":"10.3389\/fonc.2021.796962","article-title":"Diffuse large B-cell lymphoma: clinical presentation and treatment outcomes from the OncoCollect Lymphoma Registry","volume":"11","author":"Nair","year":"2021","journal-title":"Front Oncol."},{"issue":"6","key":"2023090805143785300_CIT0029","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.canep.2015.08.015","article-title":"Impact of age and socioeconomic status on treatment and survival from aggressive lymphoma: a UK population-based study of diffuse large B-cell lymphoma","volume":"39","author":"Smith","year":"2015","journal-title":"Cancer Epidemiol"},{"issue":"5","key":"2023090805143785300_CIT0030","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/QAI.0b013e31820bb06a","article-title":"Changing pattern of lymphoma subgroups at a tertiary academic complex in a high-prevalence HIV setting: a South African perspective","volume":"56","author":"Wiggill","year":"2011","journal-title":"J Acquir Immune Defic Syndr."},{"issue":"10","key":"2023090805143785300_CIT0031","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.3324\/haematol.2016.148809","article-title":"Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the International Non-Hodgkin Lymphoma Classification Project","volume":"101","author":"Perry","year":"2016","journal-title":"Haematologica."},{"issue":"1","key":"2023090805143785300_CIT0032","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/s12889-020-8368-7","article-title":"Socio-economic inequalities in the multiple dimensions of access to healthcare: the case of South Africa","volume":"20","author":"Gordon","year":"2020","journal-title":"BMC Public Health"},{"issue":"9858","key":"2023090805143785300_CIT0033","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1016\/S0140-6736(12)61814-5","article-title":"Health in South Africa: changes and challenges since 2009","volume":"380","author":"Mayosi","year":"2012","journal-title":"Lancet."},{"key":"2023090805143785300_CIT0034","article-title":"P0302-Mid-year population estimates","volume-title":"Statistics South Africa.","author":"Release","year":"2019"},{"key":"2023090805143785300_CIT0035","first-page":"1","article-title":"Diffuse large B-cell lymphoma in a high human immunodeficiency virus (HIV) prevalence, low-resource setting. S. Afr.J Oncol.","author":"Magangane","year":"2020"},{"issue":"26","key":"2023090805143785300_CIT0036","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1200\/JCO.20.00999","article-title":"Positron emission tomography-directed therapy for patients with limited-stage diffuse large B-cell lymphoma: results of Intergroup National Clinical Trials Network Study S1001","volume":"38","author":"Persky","year":"2020","journal-title":"J Clin Oncol."},{"issue":"1","key":"2023090805143785300_CIT0037","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41408-020-00403-1","article-title":"Incidence of relapsed\/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden","volume":"11","author":"Harrysson","year":"2021","journal-title":"Blood Cancer J."},{"issue":"23","key":"2023090805143785300_CIT0038","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1182\/blood-2013-07-517110","article-title":"Socioeconomic disparities in mortality after diffuse large B-cell lymphoma in the modern treatment era","volume":"123","author":"Tao","year":"2014","journal-title":"Blood."},{"issue":"9","key":"2023090805143785300_CIT0039","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.clml.2016.06.003","article-title":"Diffuse large B-cell lymphoma in the elderly: real world outcomes of immunochemotherapy in Asian population","volume":"16","author":"Byun","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"2023090805143785300_CIT0040","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol."},{"issue":"15","key":"2023090805143785300_CIT0041","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1097\/CM9.0000000000000354","article-title":"A retrospective analysis of real-world outcomes of elderly Chinese patients with diffuse large B-cell lymphoma","volume":"132","author":"Liu","year":"2019","journal-title":"Chin Med J."},{"key":"2023090805143785300_CIT0042","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ejca.2018.05.006","article-title":"Treatment strategies and outcomes in diffuse large B-cell lymphoma among 1011 patients aged 75 years or older: a Danish population-based cohort study","volume":"99","author":"Juul","year":"2018","journal-title":"Eur J Cancer."},{"issue":"9","key":"2023090805143785300_CIT0043","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1080\/10428194.2020.1765233","article-title":"A real-world study of first-line therapy in 280 consecutive Swedish patients \u226580 years with newly diagnosed diffuse large B-cell lymphoma: very elderly (\u226585 years) do well on curative intended therapy","volume":"61","author":"Asklid","year":"2020","journal-title":"Leuk Lymphoma."},{"issue":"5","key":"2023090805143785300_CIT0044","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S1470-2045(11)70069-9","article-title":"Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial","volume":"12","author":"Peyrade","year":"2011","journal-title":"Lancet Oncol."},{"issue":"8","key":"2023090805143785300_CIT0045","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.3109\/10428194.2015.1120866","article-title":"The role of radiotherapy for patients over age 60 with diffuse large B-cell lymphoma in the rituximab era","volume":"57","author":"Cassidy","year":"2016","journal-title":"Leuk Lymphoma."},{"issue":"8","key":"2023090805143785300_CIT0046","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/RLU.0000000000001718","article-title":"Multicenter comparison of contrast-enhanced FDG PET\/CT and 64-slice multi-detector-row CT for initial staging and response evaluation at the end of treatment in patients with lymphoma","volume":"42","author":"G\u00f3mez Le\u00f3n","year":"2017","journal-title":"Clin Nucl Med"},{"key":"2023090805143785300_CIT0047","doi-asserted-by":"crossref","first-page":"e926544","DOI":"10.12659\/MSM.926544","article-title":"Addressing global inequities in positron emission tomography-computed tomography (PET-CT) for cancer management: a statistical model to guide strategic planning","volume":"26","author":"Gallach","year":"2020","journal-title":"Med Sci Monit."},{"issue":"2","key":"2023090805143785300_CIT0048","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3892\/ol.2020.12393","article-title":"Predictive value of baseline (18)F-FDG PET\/CT and interim treatment response for the prognosis of patients with diffuse large B-cell lymphoma receiving R-CHOP chemotherapy","volume":"21","author":"Zhu","year":"2021","journal-title":"Oncol Lett"},{"issue":"52","key":"2023090805143785300_CIT0049","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.18632\/oncotarget.27103","article-title":"Predictive value of interim FDG-PET\/CT findings in patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"10","author":"Kitajima","year":"2019","journal-title":"Oncotarget"},{"issue":"3","key":"2023090805143785300_CIT0050","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/bjh.16875","article-title":"FDG-PET\/CT after two cycles of R-CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome - final result of a UK National Cancer Research Institute prospective study","volume":"192","author":"Mikhaeel","year":"2021","journal-title":"Br J Haematol."}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/9\/e756\/51436998\/oyad069.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/9\/e756\/51436998\/oyad069.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T01:15:11Z","timestamp":1694135711000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/28\/9\/e756\/7117811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,13]]},"references-count":50,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,4,13]]},"published-print":{"date-parts":[[2023,9,7]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyad069","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9,1]]},"published":{"date-parts":[[2023,4,13]]}}}